false
0001320414
0001320414
2024-10-31
2024-10-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
current
report
Pursuant to Section 13
or 15(d) of the
Securities Exchange
Act of 1934
Date of
Report (Date of earliest event reported): October 31, 2024
SELECT MEDICAL HOLDINGS CORPORATION
(Exact name of registrant
as specified in its charter)
| Delaware | |
001-34465 | |
20-1764048 |
(State or other jurisdiction of
Incorporation) | |
(Commission File
Number) | |
(I.R.S. Employer
Identification No.) |
4714 Gettysburg Road, P.O. Box 2034
Mechanicsburg, PA 17055
(Address of principal executive offices) (Zip Code)
(717) 972-1100
(Registrant’s telephone number, including
area code)
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
SEM |
New York Stock Exchange (NYSE) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether either registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if either
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On
October 31, 2024, Select Medical Holdings Corporation (the “Company”) issued a press release announcing its financial
results for its third quarter ended September 30, 2024. A copy of the press release and financial schedules are attached as Exhibit 99.1
to this report and incorporated herein by reference.
The information in this report
(including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act.
Dividend Declaration
On October 30, 2024,
the Company’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about November 26,
2024 to stockholders of record as of the close of business on November 13, 2024.
| Item 9.01 | Financial
Statements and Exhibits. |
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | SELECT MEDICAL HOLDINGS CORPORATION |
| | |
| Date: October 31, 2024 | By: |
/s/ Michael E. Tarvin |
| | |
Michael E. Tarvin |
| | |
Senior Executive Vice President, General Counsel and Secretary |
Exhibit 99.1
| FOR IMMEDIATE RELEASE |
4714 Gettysburg Road
Mechanicsburg, PA 17055
NYSE Symbol: SEM |
Select Medical Holdings Corporation Announces
Results
For Its Third Quarter Ended September 30,
2024 and Cash Dividend
MECHANICSBURG, PENNSYLVANIA
— October 31, 2024 — Select Medical Holdings Corporation (“Select Medical,” “we,” “us,”
or “our”) (NYSE: SEM) today announced results for its third quarter ended September 30, 2024, and the declaration of
a cash dividend.
For the third quarter ended
September 30, 2024, revenue increased 5.7% to $1,761.2 million, compared to $1,665.7 million for the same quarter, prior year. Income
from operations increased 8.6% to $141.1 million for the third quarter ended September 30, 2024, compared to $130.0 million
for the same quarter, prior year. Net income increased 33.2% to $81.0 million for the third quarter ended September 30, 2024, compared
to $60.8 million for the same quarter, prior year. Adjusted EBITDA increased 6.0% to $205.5 million for the third quarter ended September 30,
2024, compared to $193.8 million for the same quarter, prior year. Earnings per common share increased 13.2% to $0.43 for the third quarter
ended September 30, 2024, compared to $0.38 for the same quarter, prior year. Adjusted earnings per common share increased 8.7% to
$0.50 for the third quarter ended September 30, 2024, compared to $0.46 for the same quarter, prior year. The definition of Adjusted
EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per
common share to adjusted earnings per common share is presented in table X of this release.
For the nine months ended
September 30, 2024, revenue increased 6.1% to $5,309.7 million, compared to $5,005.2 million for the same period, prior year. Income
from operations increased 11.9% to $492.9 million for the nine months ended September 30, 2024, compared to $440.6 million for the
same period, prior year. Net income increased 23.1% to $292.9 million for the nine months ended September 30, 2024, compared to $237.9
million for the same period, prior year. Adjusted EBITDA increased 10.6% to $693.7 million for the nine months ended September 30,
2024, compared to $627.4 million for the same period, prior year. Earnings per common share increased 14.8% to $1.78 for the nine months
ended September 30, 2024, compared to $1.55 for the same period, prior year. Adjusted earnings per common share increased 14.1% to
$1.86 for the nine months ended September 30, 2024, compared to $1.63 for the same period, prior year. The definition of Adjusted
EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per
common share to adjusted earnings per common share is presented in table X of this release.
Company Overview
Select Medical is one of
the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational
health centers in the United States based on number of facilities. Select Medical’s reportable segments include the critical illness
recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As
of September 30, 2024, Select Medical operated 106 critical illness recovery hospitals in 29 states, 34 rehabilitation hospitals
in 13 states, 1,925 outpatient rehabilitation clinics in 39 states and the District of Columbia, and 549 occupational health centers
in 41 states. At September 30, 2024, Select Medical had operations in 46 states and the District of Columbia. Information about
Select Medical is available at www.selectmedical.com.
Critical Illness Recovery Hospital Segment
For the third quarter ended
September 30, 2024, revenue for the critical illness recovery hospital segment increased 3.4% to $583.0 million, compared to $563.6
million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 9.5% to $50.8 million
for the third quarter ended September 30, 2024, compared to $46.4 million for the same quarter, prior year. The Adjusted EBITDA margin
for the critical illness recovery hospital segment was 8.7% for the third quarter ended September 30, 2024, compared to 8.2% for
the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table VII of this release for
the third quarters ended September 30, 2024 and 2023.
For the nine months ended
September 30, 2024, revenue for the critical illness recovery hospital segment increased 6.4% to $1,843.8 million, compared to $1,732.6
million for the same period, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 26.5% to $238.5
million for the nine months ended September 30, 2024, compared to $188.6 million for the same period, prior year. The Adjusted EBITDA
margin for the critical illness recovery hospital segment was 12.9% for the nine months ended September 30, 2024, compared to 10.9%
for the same period, prior year. Certain critical illness recovery hospital key statistics are presented in table VIII of this release
for the nine months ended September 30, 2024 and 2023.
Rehabilitation Hospital Segment
For the third quarter ended
September 30, 2024, revenue for the rehabilitation hospital segment increased 14.4% to $282.7 million, compared to $247.1 million
for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 12.1% to $60.1 million for the third
quarter ended September 30, 2024, compared to $53.6 million for the same quarter, prior year. The Adjusted EBITDA margin for the
rehabilitation hospital segment was 21.3% for the third quarter ended September 30, 2024, compared to 21.7% for the same quarter,
prior year. Certain rehabilitation hospital key statistics are presented in table VII of this release for the third quarters ended September 30,
2024 and 2023.
For the nine months ended
September 30, 2024, revenue for the rehabilitation hospital segment increased 13.5% to $816.2 million, compared to $719.4 million
for the same period, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 18.0% to $183.5 million for the nine
months ended September 30, 2024, compared to $155.5 million for the same period, prior year. The Adjusted EBITDA margin for the rehabilitation
hospital segment was 22.5% for the nine months ended September 30, 2024, compared to 21.6% for the same period, prior year. Certain
rehabilitation hospital key statistics are presented in table VIII of this release for the nine months ended September 30, 2024 and
2023.
Outpatient Rehabilitation Segment
For the third quarter ended
September 30, 2024, revenue for the outpatient rehabilitation segment increased 6.9% to $312.0 million, compared to $291.8 million
for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 7.5% to $28.3 million for the third
quarter ended September 30, 2024, compared to $26.3 million for the same quarter, prior year. The Adjusted EBITDA margin for the
outpatient rehabilitation segment was 9.1% for the third quarter ended September 30, 2024, compared to 9.0% for the same quarter,
prior year. Certain outpatient rehabilitation key statistics are presented in table VII of this release for the third quarters ended September 30,
2024 and 2023.
For the nine months ended
September 30, 2024, revenue for the outpatient rehabilitation segment increased 4.5% to $930.7 million, compared to $890.7 million
for the same period, prior year. Adjusted EBITDA for the outpatient rehabilitation segment was $82.0 million for the nine months ended
September 30, 2024, compared to $89.4 million for the same period, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation
segment was 8.8% for the nine months ended September 30, 2024, compared to 10.0% for the same period, prior year. Certain outpatient
rehabilitation key statistics are presented in table VIII of this release for the nine months ended September 30, 2024 and 2023.
Concentra Segment
For the third quarter ended
September 30, 2024, revenue for the Concentra segment increased 3.3% to $489.6 million, compared to $474.0 million for the same quarter,
prior year. Adjusted EBITDA for the Concentra segment increased 2.7% to $101.6 million for the third quarter ended September 30,
2024, compared to $98.9 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 20.7% for the
third quarter ended September 30, 2024, compared to 20.9% for the same quarter, prior year. Certain Concentra key statistics are
presented in table VII of this release for the third quarters ended September 30, 2024 and 2023.
For the nine months ended
September 30, 2024, revenue for the Concentra segment increased 2.7% to $1,435.2 million, compared to $1,397.3 million for the same
period, prior year. Adjusted EBITDA for the Concentra segment increased 2.1% to $299.3 million for the nine months ended September 30,
2024, compared to $293.0 million for the same period, prior year. The Adjusted EBITDA margin for the Concentra segment was 20.9% for the
nine months ended September 30, 2024, compared to 21.0% for the same period, prior year. Certain Concentra key statistics are presented
in table VIII of this release for the nine months ended September 30, 2024 and 2023.
Dividend
On October 30, 2024,
Select Medical’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about November 26,
2024, to stockholders of record as of the close of business on November 13, 2024.
There is no assurance that
future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of Select Medical’s
Board of Directors after taking into account various factors, including, but not limited to, Select Medical’s financial condition,
operating results, available cash and current and anticipated cash needs, the terms of Select Medical’s indebtedness, and other
factors Select Medical’s Board of Directors may deem to be relevant.
Stock Repurchase Program
The Board of Directors of
Select Medical has authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock.
The common stock repurchase program will remain in effect until December 31, 2025, unless further extended or earlier terminated
by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions,
and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings
under its revolving credit facility.
Select Medical did not repurchase
shares under its authorized stock repurchase program during the nine months ended September 30, 2024. Since the inception of the
common stock repurchase program through September 30, 2024, Select Medical has repurchased 48,234,823 shares at a cost of approximately
$600.3 million, or $12.45 per share, which includes transaction costs.
Concentra Group Holdings Parent Initial Public
Offering and Debt Transactions
On July 26, 2024, Concentra
Group Holdings Parent (“Concentra”), a then wholly-owned subsidiary of Select, completed an initial public offering (“IPO”)
of 22,500,000 shares of its common stock, par value $0.01 per share, at an initial public offering price of $23.50 per share for for net
proceeds of $499.7 million after deducting underwriting discounts and commission of $29.1 million. In addition, the underwriters
exercised the option to purchase an additional 750,000 shares of the Concentra’s common stock for net proceeds of $16.7 million
after deducting discounts and commission of $1.0 million. Concentra shares began trading on the New York Stock Exchange under the
symbol “CON” on July 25, 2024.
In connection with the offering,
Concentra Health Services, Inc. (“CHSI”), a then wholly-owned subsidiary of Concentra, entered into certain financing
arrangements which include Credit Facilities and the issuance of $650.0 million aggregate principal amount of 6.875% Senior Notes
due 2032 (the “Notes”). The Notes are unconditionally guaranteed, jointly and severally, on a senior unsecured basis by Concentra
and certain of its wholly-owned subsidiaries. The Notes bear interest at a rate of 6.875% per annum and mature on July 15, 2032.
The Credit Facilities consist of a $850.0 million Term Loan and a $400.0 million Revolving Credit Facility. The Revolving Credit
Facility was undrawn at the time of closing. The Term Loan matures on July 26, 2031, and has an interest rate of Term SOFR plus a
percentage ranging from 2.00% to 2.25%, subject to a leverage-based pricing grid. The Revolving Credit Facility matures on July 26,
2029, and has an interest rate of Term SOFR plus a percentage ranging from 2.25% to 2.75%, subject to a leverage-based pricing grid.
The net proceeds of the IPO
and the debt financing transactions, except for $34.7 million, were used to repay approximately $1.9 billion of Select’s
Credit Facilities.
Business Outlook
Select Medical is updating
its 2024 business outlook, which was provided most recently in its August 1, 2024, press release. Select Medical expects revenue
to be in the range of $6.95 billion to $7.15 billion, Adjusted EBITDA to be in the range of $865.0 million to $885.0 million, fully diluted
earnings per share to be in the range of $2.01 to $2.12 and adjusted earnings per share to be in the range of $2.09 to $2.20. Reconciliations
of full year 2024 Adjusted EBITDA expectations to net income and adjusted earnings per share to fully diluted earnings per share are presented
in table XI of this release.
Conference Call
Select Medical will host
a conference call regarding its third quarter results and its business outlook on Friday, November 1, 2024, at 9:00am ET. The conference
call will be a live webcast and can be accessed at Select Medical Holdings Corporation’s website at www.selectmedicalholdings.com.
A replay of the webcast will be available shortly after the call through the same link.
For listeners wishing to
dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Select Medical Earnings
Call Registration to obtain your dial-in number and unique passcode.
* * * * *
Certain statements contained
herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private
Securities Litigation Reform Act of 1995), including statements related to Select Medical’s 2024 and long-term business outlook.
Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such
forward-looking statements due to factors including the following:
| · | changes in government reimbursement for our services and/or new payment policies may result in a reduction
in revenue, an increase in costs, and a reduction in profitability; |
| · | adverse economic conditions including an inflationary environment could cause us to continue to experience
increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results,
cash flows, and financial condition; |
| · | shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability
to attract or retain qualified healthcare professionals could limit our ability to staff our facilities; |
| · | shortages in qualified health professionals could cause us to increase our dependence on contract labor,
increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase
our operating costs significantly; |
| · | public threats such as a global pandemic, or widespread outbreak of an infectious disease, similar to
the COVID-19 pandemic, could negatively impact patient volumes and revenues, increase labor and other operating costs, disrupt global
financial markets, and/or further legislative and regulatory actions which impact healthcare providers, including actions that may impact
the Medicare program; |
| · | the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities
to maintain their Medicare certifications may cause our revenue and profitability to decline; |
| · | the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities
operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our revenue
and profitability to decline; |
| · | a government investigation or assertion that we have violated applicable regulations may result in sanctions
or reputational harm and increased costs; |
| · | acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose
us to unforeseen liabilities; |
| · | our plans and expectations related to our acquisitions and our ability to realize anticipated synergies; |
| · | failure to complete or achieve some or all the expected benefits of the potential separation of Concentra; |
| · | private third-party payors for our services may adopt payment policies that could limit our future revenue
and profitability; |
| · | the failure to maintain established relationships with the physicians in the areas we serve could reduce
our revenue and profitability; |
| · | competition may limit our ability to grow and result in a decrease in our revenue and profitability; |
| · | the loss of key members of our management team could significantly disrupt our operations; |
| · | the effect of claims asserted against us could subject us to substantial uninsured liabilities; |
| · | a security breach of our or our third-party vendors’ information technology systems may subject
us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of
1996 or the Health Information Technology for Economic and Clinical Health Act; and |
| · | other factors discussed from time to time in our filings with the Securities and Exchange Commission (the
“SEC”), including factors discussed under the heading “Risk Factors” of the annual report on Form 10-K for
the year ended December 31, 2023. |
Except as required by applicable
law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly
update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not
place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements
are reasonable, we cannot guarantee future results or performance.
Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
ir@selectmedical.com
SOURCE: Select Medical Holdings Corporation
I. Condensed Consolidated Statements of Operations
For the Three Months Ended September 30, 2023 and 2024
(In thousands, except per share amounts, unaudited)
| | |
2023 | | |
2024 | | |
% Change | |
| Revenue | |
$ | 1,665,694 | | |
$ | 1,761,220 | | |
| 5.7 | % |
| Costs and expenses: | |
| | | |
| | | |
| | |
| Cost of services, exclusive of depreciation and amortization | |
| 1,442,509 | | |
| 1,523,899 | | |
| 5.6 | |
| General and administrative | |
| 41,316 | | |
| 47,347 | | |
| 14.6 | |
| Depreciation and amortization | |
| 52,394 | | |
| 50,143 | | |
| (4.3 | ) |
| Total costs and expenses | |
| 1,536,219 | | |
| 1,621,389 | | |
| 5.5 | |
| Other operating income | |
| 485 | | |
| 1,302 | | |
| N/M | |
| Income from operations | |
| 129,960 | | |
| 141,133 | | |
| 8.6 | |
| Other income and expense: | |
| | | |
| | | |
| | |
| Loss on early retirement of debt | |
| (14,692 | ) | |
| (10,939 | ) | |
| N/M | |
| Equity in earnings of unconsolidated subsidiaries | |
| 11,561 | | |
| 33,069 | | |
| 186.0 | |
| Interest expense | |
| (50,271 | ) | |
| (55,439 | ) | |
| 10.3 | |
| Income before income taxes | |
| 76,558 | | |
| 107,824 | | |
| 40.8 | |
| Income tax expense | |
| 15,742 | | |
| 26,809 | | |
| 70.3 | |
| Net income | |
| 60,816 | | |
| 81,015 | | |
| 33.2 | |
| Less: Net income attributable to non-controlling interests | |
| 12,636 | | |
| 25,387 | | |
| 100.9 | |
| Net income attributable to Select Medical | |
$ | 48,180 | | |
$ | 55,628 | | |
| 15.5 | % |
| Basic and diluted earnings per common share:(1) | |
$ | 0.38 | | |
$ | 0.43 | | |
| | |
| (1) | Refer to table III for calculation of earnings per common share. |
| | |
| N/M |
Not meaningful |
II. Condensed Consolidated Statements of Operations
For the Nine Months Ended September 30, 2023 and 2024
(In thousands, except per share amounts, unaudited)
| | |
2023 | | |
2024 | | |
% Change | |
| Revenue | |
$ | 5,005,202 | | |
$ | 5,309,692 | | |
| 6.1 | % |
| Costs and expenses: | |
| | | |
| | | |
| | |
| Cost of services, exclusive of depreciation and amortization | |
| 4,284,931 | | |
| 4,516,553 | | |
| 5.4 | |
| General and administrative | |
| 126,103 | | |
| 145,672 | | |
| 15.5 | |
| Depreciation and amortization | |
| 154,758 | | |
| 158,151 | | |
| 2.2 | |
| Total costs and expenses | |
| 4,565,792 | | |
| 4,820,376 | | |
| 5.6 | |
| Other operating income | |
| 1,211 | | |
| 3,584 | | |
| N/M | |
| Income from operations | |
| 440,621 | | |
| 492,900 | | |
| 11.9 | |
| Other income and expense: | |
| | | |
| | | |
| | |
| Loss on early retirement of debt | |
| (14,692 | ) | |
| (10,939 | ) | |
| N/M | |
| Equity in earnings of unconsolidated subsidiaries | |
| 30,618 | | |
| 49,805 | | |
| 62.7 | |
| Interest expense | |
| (147,839 | ) | |
| (143,309 | ) | |
| (3.1 | ) |
| Income before income taxes | |
| 308,708 | | |
| 388,457 | | |
| 25.8 | |
| Income tax expense | |
| 70,775 | | |
| 95,509 | | |
| 34.9 | |
| Net income | |
| 237,933 | | |
| 292,948 | | |
| 23.1 | |
| Less: Net income attributable to non-controlling interests | |
| 40,711 | | |
| 62,860 | | |
| 54.4 | |
| Net income attributable to Select Medical | |
$ | 197,222 | | |
$ | 230,088 | | |
| 16.7 | % |
| Basic and diluted earnings per common share:(1) | |
$ | 1.55 | | |
$ | 1.78 | | |
| | |
(1) Refer
to table III for calculation of earnings per common share.
N/M Not meaningful
III. Earnings per Share
For the Three and Nine Months Ended September 30,
2023 and 2024
(In thousands, except per share amounts, unaudited)
Select Medical’s capital
structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), Select Medical
applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate
equally with its common stock in undistributed earnings.
The following table sets
forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the
three and nine months ended September 30, 2023 and 2024:
| | |
Basic and Diluted EPS | |
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2023 | | |
2024 | | |
2023 | | |
2024 | |
| Net income | |
$ | 60,816 | | |
$ | 81,015 | | |
$ | 237,933 | | |
$ | 292,948 | |
| Less: net income attributable to non-controlling interests | |
| 12,636 | | |
| 25,387 | | |
| 40,711 | | |
| 62,860 | |
| Net income attributable to Select Medical | |
| 48,180 | | |
| 55,628 | | |
| 197,222 | | |
| 230,088 | |
| Less: net income attributable to participating securities | |
| 1,722 | | |
| 2,145 | | |
| 7,155 | | |
| 8,935 | |
| Net income attributable to common shares | |
$ | 46,458 | | |
$ | 53,483 | | |
$ | 190,067 | | |
$ | 221,153 | |
The following tables set
forth the computation of EPS under the two-class method for the three and nine months ended September 30, 2023 and 2024:
| | |
Three Months Ended September 30, | |
| | |
2023 | | |
2024 | |
| | |
Net Income
Allocation | | |
Shares(1) | | |
Basic and
Diluted EPS | | |
Net Income
Allocation | | |
Shares(1) | | |
Basic and
Diluted EPS | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| | |
(in thousands, except for per share amounts) | |
| Common shares | |
$ | 46,458 | | |
| 123,400 | | |
$ | 0.38 | | |
$ | 53,483 | | |
| 124,714 | | |
$ | 0.43 | |
| Participating securities | |
| 1,722 | | |
| 4,574 | | |
$ | 0.38 | | |
| 2,145 | | |
| 5,001 | | |
$ | 0.43 | |
| Total | |
$ | 48,180 | | |
| | | |
| | | |
$ | 55,628 | | |
| | | |
| | |
| | |
Nine Months Ended September 30, | |
| | |
2023 | | |
2024 | |
| | |
Net Income
Allocation | | |
Shares(1) | | |
Basic and
Diluted EPS | | |
Net Income
Allocation | | |
Shares(1) | | |
Basic and
Diluted EPS | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| | |
(in thousands, except for per share amounts) | |
| Common shares | |
$ | 190,067 | | |
| 122,865 | | |
$ | 1.55 | | |
$ | 221,153 | | |
| 124,175 | | |
$ | 1.78 | |
| Participating securities | |
| 7,155 | | |
| 4,625 | | |
$ | 1.55 | | |
| 8,935 | | |
| 5,017 | | |
$ | 1.78 | |
| Total | |
$ | 197,222 | | |
| | | |
| | | |
$ | 230,088 | | |
| | | |
| | |
(1) Represents
the weighted average share count outstanding during the period.
IV. Condensed Consolidated Balance Sheets
(In thousands, unaudited)
| | |
December 31, 2023 | | |
September 30, 2024 | |
| Assets | |
| | | |
| | |
| Current Assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 84,006 | | |
$ | 191,468 | |
| Accounts receivable | |
| 940,335 | | |
| 1,060,007 | |
| Other current assets | |
| 233,305 | | |
| 152,722 | |
| Total Current Assets | |
| 1,257,646 | | |
| 1,404,197 | |
| Operating lease right-of-use assets | |
| 1,188,616 | | |
| 1,321,045 | |
| Property and equipment, net | |
| 1,023,561 | | |
| 1,040,383 | |
| Goodwill | |
| 3,513,170 | | |
| 3,555,022 | |
| Identifiable intangible assets, net | |
| 329,916 | | |
| 312,565 | |
| Other assets | |
| 376,722 | | |
| 369,449 | |
| Total Assets | |
$ | 7,689,631 | | |
$ | 8,002,661 | |
| Liabilities and Equity | |
| | | |
| | |
| Current Liabilities: | |
| | | |
| | |
| Payables and accruals | |
$ | 932,736 | | |
$ | 953,087 | |
| Current operating lease liabilities | |
| 245,400 | | |
| 249,832 | |
| Current portion of long-term debt and notes payable | |
| 70,329 | | |
| 42,785 | |
| Total Current Liabilities | |
| 1,248,465 | | |
| 1,245,704 | |
| Non-current operating lease liabilities | |
| 1,025,867 | | |
| 1,163,406 | |
| Long-term debt, net of current portion | |
| 3,587,675 | | |
| 3,098,957 | |
| Non-current deferred tax liability | |
| 143,306 | | |
| 95,557 | |
| Other non-current liabilities | |
| 110,303 | | |
| 98,593 | |
| Total Liabilities | |
| 6,115,616 | | |
| 5,702,217 | |
| Redeemable non-controlling interests | |
| 26,297 | | |
| 30,455 | |
| Total equity | |
| 1,547,718 | | |
| 2,269,989 | |
| Total Liabilities and Equity | |
$ | 7,689,631 | | |
$ | 8,002,661 | |
V. Condensed Consolidated Statements of Cash
Flows
For the Three Months Ended September 30,
2023 and 2024
(In thousands, unaudited)
| | |
2023 | | |
2024 | |
| Operating activities | |
| | | |
| | |
| Net income | |
$ | 60,816 | | |
$ | 81,015 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
| Distributions from unconsolidated subsidiaries | |
| 1,055 | | |
| 16,306 | |
| Depreciation and amortization | |
| 52,394 | | |
| 50,143 | |
| Provision for expected credit losses | |
| 340 | | |
| 199 | |
| Equity in earnings of unconsolidated subsidiaries | |
| (11,561 | ) | |
| (33,069 | ) |
| Loss on extinguishment of debt | |
| 175 | | |
| 10,939 | |
| (Gain) loss on sale or disposal of assets | |
| 16 | | |
| (89 | ) |
| Stock compensation expense | |
| 11,483 | | |
| 13,376 | |
| Amortization of debt discount, premium and issuance costs | |
| 725 | | |
| 787 | |
| Deferred income taxes | |
| (6,173 | ) | |
| (602 | ) |
| Changes in operating assets and liabilities, net of effects of business combinations: | |
| | | |
| | |
| Accounts receivable | |
| 20,121 | | |
| 22,348 | |
| Other current assets | |
| (11,279 | ) | |
| 1,299 | |
| Other assets | |
| 1,556 | | |
| 26,789 | |
| Accounts payable and accrued expenses | |
| (3,330 | ) | |
| (8,472 | ) |
| Net cash provided by operating activities | |
| 116,338 | | |
| 180,969 | |
| Investing activities | |
| | | |
| | |
| Business combinations, net of cash acquired | |
| (12,750 | ) | |
| 3,682 | |
| Purchases of property, equipment, and other assets | |
| (50,198 | ) | |
| (50,683 | ) |
| Investment in businesses | |
| (74 | ) | |
| — | |
| Proceeds from sale of assets and businesses | |
| 4 | | |
| 1,908 | |
| Net cash used in investing activities | |
| (63,018 | ) | |
| (45,093 | ) |
| Financing activities | |
| | | |
| | |
| Borrowings on revolving facilities | |
| 200,000 | | |
| 235,000 | |
| Payments on revolving facilities | |
| (205,000 | ) | |
| (570,000 | ) |
| Proceeds from term loans | |
| 2,092,232 | | |
| 836,697 | |
| Payments on term loans | |
| (2,108,694 | ) | |
| (1,640,418 | ) |
| Proceeds from 6.875% senior notes, net of issuance costs | |
| — | | |
| 637,337 | |
| Borrowings of other debt | |
| 8,551 | | |
| 3,078 | |
| Principal payments on other debt | |
| (11,925 | ) | |
| (12,521 | ) |
| Dividends paid to common stockholders | |
| (16,035 | ) | |
| (16,194 | ) |
| Repurchase of common stock | |
| (9,544 | ) | |
| (16,524 | ) |
| Decrease in overdrafts | |
| (1,500 | ) | |
| (9,453 | ) |
| Proceeds from issuance of non-controlling interests | |
| 5,651 | | |
| 3,662 | |
| Distributions to and purchases of non-controlling interests | |
| (30,783 | ) | |
| (17,430 | ) |
| Proceeds from Concentra initial public offering | |
| — | | |
| 511,198 | |
| Net cash used in financing activities | |
| (77,047 | ) | |
| (55,568 | ) |
| Net increase (decrease) in cash and cash equivalents | |
| (23,727 | ) | |
| 80,308 | |
| Cash and cash equivalents at beginning of period | |
| 101,167 | | |
| 111,160 | |
| Cash and cash equivalents at end of period | |
$ | 77,440 | | |
$ | 191,468 | |
| Supplemental information | |
| | | |
| | |
| Cash paid for interest, excluding amounts received of $22,069 and $23,115 under interest rate cap contract | |
$ | 88,116 | | |
$ | 74,879 | |
| Cash paid for taxes | |
| 35,747 | | |
| 41,870 | |
VI. Condensed Consolidated Statements of Cash
Flows
For the Nine Months Ended September 30,
2023 and 2024
(In thousands, unaudited)
| | |
2023 | | |
2024 | |
| Operating activities | |
| | | |
| | |
| Net income | |
$ | 237,933 | | |
$ | 292,948 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
| Distributions from unconsolidated subsidiaries | |
| 9,896 | | |
| 30,436 | |
| Depreciation and amortization | |
| 154,758 | | |
| 158,151 | |
| Provision for expected credit losses | |
| 1,101 | | |
| 1,659 | |
| Equity in earnings of unconsolidated subsidiaries | |
| (30,618 | ) | |
| (49,805 | ) |
| Loss on extinguishment of debt | |
| 175 | | |
| 10,939 | |
| Gain on sale or disposal of assets | |
| (7 | ) | |
| (1,111 | ) |
| Stock compensation expense | |
| 31,991 | | |
| 39,399 | |
| Amortization of debt discount, premium, and issuance costs | |
| 1,899 | | |
| 2,279 | |
| Deferred income taxes | |
| (17,049 | ) | |
| (34,941 | ) |
| Changes in operating assets and liabilities, net of effects of business combinations: | |
| | | |
| | |
| Accounts receivable | |
| (3,014 | ) | |
| (116,761 | ) |
| Other current assets | |
| (17,276 | ) | |
| 7,856 | |
| Other assets | |
| 7,028 | | |
| 13,942 | |
| Accounts payable and accrued expenses | |
| 25,799 | | |
| 37,441 | |
| Net cash provided by operating activities | |
| 402,616 | | |
| 392,432 | |
| Investing activities | |
| | | |
| | |
| Business combinations, net of cash acquired | |
| (20,482 | ) | |
| (2,311 | ) |
| Purchases of property, equipment, and other assets | |
| (168,597 | ) | |
| (158,748 | ) |
| Investment in businesses | |
| (9,874 | ) | |
| — | |
| Proceeds from sale of assets and businesses | |
| 60 | | |
| 4,241 | |
| Net cash used in investing activities | |
| (198,893 | ) | |
| (156,818 | ) |
| Financing activities | |
| | | |
| | |
| Borrowings on revolving facilities | |
| 635,000 | | |
| 950,000 | |
| Payments on revolving facilities | |
| (740,000 | ) | |
| (1,220,000 | ) |
| Proceeds from term loans, net of issuance costs | |
| 2,092,232 | | |
| 836,697 | |
| Payments on term loans | |
| (2,108,694 | ) | |
| (1,719,503 | ) |
| Proceeds from 6.875% senior notes, net of issuance costs | |
| — | | |
| 637,337 | |
| Borrowings of other debt | |
| 30,849 | | |
| 20,806 | |
| Principal payments on other debt | |
| (38,298 | ) | |
| (35,782 | ) |
| Dividends paid to common stockholders | |
| (47,856 | ) | |
| (48,493 | ) |
| Repurchase of common stock | |
| (11,050 | ) | |
| (17,924 | ) |
| Decrease in overdrafts | |
| (1,967 | ) | |
| (16,101 | ) |
| Proceeds from issuance of non-controlling interests | |
| 20,463 | | |
| 9,413 | |
| Distributions to and purchases of non-controlling interests | |
| (54,868 | ) | |
| (35,800 | ) |
| Proceeds from Concentra initial public offering | |
| — | | |
| 511,198 | |
| Net cash used in financing activities | |
| (224,189 | ) | |
| (128,152 | ) |
| Net increase (decrease) in cash and cash equivalents | |
| (20,466 | ) | |
| 107,462 | |
| Cash and cash equivalents at beginning of period | |
| 97,906 | | |
| 84,006 | |
| Cash and cash equivalents at end of period | |
$ | 77,440 | | |
$ | 191,468 | |
| Supplemental information | |
| | | |
| | |
| Cash paid for interest, excluding amounts received of $60,353 and $68,069 under the interest rate cap contract | |
$ | 221,697 | | |
$ | 216,757 | |
| Cash paid for taxes | |
| 78,502 | | |
| 102,696 | |
VII. Key Statistics
For the Three Months Ended September 30, 2023, and 2024
(unaudited)
| | |
2023 | | |
2024 | | |
% Change | |
| Critical Illness Recovery Hospital | |
| | | |
| | | |
| | |
| Number of hospitals operated – end of period(a) | |
| 107 | | |
| 106 | | |
| | |
| Revenue (,000) | |
$ | 563,628 | | |
$ | 582,950 | | |
| 3.4 | % |
| Number of patient days(b)(c) | |
| 267,910 | | |
| 270,760 | | |
| 1.1 | % |
| Number of admissions(b)(d) | |
| 8,736 | | |
| 8,676 | | |
| (0.7 | )% |
| Revenue per patient day(b)(e) | |
$ | 2,095 | | |
$ | 2,145 | | |
| 2.4 | % |
| Occupancy rate(b)(f) | |
| 64 | % | |
| 65 | % | |
| 1.6 | % |
| Adjusted EBITDA (,000) | |
$ | 46,362 | | |
$ | 50,763 | | |
| 9.5 | % |
| Adjusted EBITDA margin | |
| 8.2 | % | |
| 8.7 | % | |
| | |
| Rehabilitation Hospital | |
| | | |
| | | |
| | |
| Number of hospitals operated – end of period(a) | |
| 33 | | |
| 34 | | |
| | |
| Revenue (,000) | |
$ | 247,101 | | |
$ | 282,709 | | |
| 14.4 | % |
| Number of patient days(b)(c) | |
| 112,095 | | |
| 116,835 | | |
| 4.2 | % |
| Number of admissions(b)(d) | |
| 7,840 | | |
| 8,439 | | |
| 7.6 | % |
| Revenue per patient day(b)(e) | |
$ | 2,025 | | |
$ | 2,148 | | |
| 6.1 | % |
| Occupancy rate(b)(f) | |
| 84 | % | |
| 82 | % | |
| (2.4 | )% |
| Adjusted EBITDA (,000) | |
$ | 53,626 | | |
$ | 60,117 | | |
| 12.1 | % |
| Adjusted EBITDA margin | |
| 21.7 | % | |
| 21.3 | % | |
| | |
| Outpatient Rehabilitation | |
| | | |
| | | |
| | |
| Number of clinics operated – end of period(a) | |
| 1,946 | | |
| 1,925 | | |
| | |
| Working days(g) | |
| 63 | | |
| 64 | | |
| | |
| Revenue (,000) | |
$ | 291,804 | | |
$ | 312,042 | | |
| 6.9 | % |
| Number of visits(b)(h) | |
| 2,627,362 | | |
| 2,773,465 | | |
| 5.6 | % |
| Revenue per visit(b)(i) | |
$ | 100 | | |
$ | 101 | | |
| 1.0 | % |
| Adjusted EBITDA (,000) | |
$ | 26,346 | | |
$ | 28,319 | | |
| 7.5 | % |
| Adjusted EBITDA margin | |
| 9.0 | % | |
| 9.1 | % | |
| | |
| Concentra | |
| | | |
| | | |
| | |
| Number of centers operated – end of period(b) | |
| 539 | | |
| 549 | | |
| | |
| Working days(g) | |
| 63 | | |
| 64 | | |
| | |
| Revenue (,000) | |
$ | 473,964 | | |
$ | 489,638 | | |
| 3.3 | % |
| Number of visits(b)(h) | |
| 3,281,042 | | |
| 3,258,605 | | |
| (0.7 | )% |
| Revenue per visit(b)(i) | |
$ | 136 | | |
$ | 141 | | |
| 3.7 | % |
| Adjusted EBITDA (,000) | |
$ | 98,907 | | |
$ | 101,571 | | |
| 2.7 | % |
| Adjusted EBITDA margin | |
| 20.9 | % | |
| 20.7 | % | |
| | |
| (a) | Includes managed locations. |
| (b) | Excludes managed locations. For purposes of the Concentra segment, onsite clinics are excluded. |
| (c) | Each patient day represents one patient occupying one bed for one day during the periods presented. |
| (d) | Represents the number of patients admitted to Select Medical’s hospitals during the periods presented. |
| (e) | Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated
by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical’s
hospitals, by the total number of patient days. |
| (f) | Represents the portion of our hospitals being utilized for patient care during the periods presented.
Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during
the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented. |
| (g) | Represents the number of days in which normal business operations were conducted during the periods presented. |
| (h) | Represents the number of visits in which patients were treated at Select Medical’s outpatient rehabilitation
clinics and Concentra centers during the periods presented. |
| (i) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated
by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes
of this computation for the Concentra segment, patient service revenue does not include onsite clinics. |
VIII. Key Statistics
For the Nine Months Ended September 30, 2023, and 2024
(unaudited)
| | |
2023 | | |
2024 | | |
% Change | |
| Critical Illness Recovery Hospital | |
| | | |
| | | |
| | |
| Number of hospitals operated – end of period(a) | |
| 107 | | |
| 106 | | |
| | |
| Revenue (,000) | |
$ | 1,732,645 | | |
$ | 1,843,751 | | |
| 6.4 | % |
| Number of patient days(b)(c) | |
| 831,022 | | |
| 844,623 | | |
| 1.6 | % |
| Number of admissions(b)(d) | |
| 27,099 | | |
| 27,093 | | |
| 0.0 | % |
| Revenue per patient day(b)(e) | |
$ | 2,076 | | |
$ | 2,175 | | |
| 4.8 | % |
| Occupancy rate(b)(f) | |
| 68 | % | |
| 68 | % | |
| 0.0 | % |
| Adjusted EBITDA (,000) | |
$ | 188,631 | | |
$ | 238,536 | | |
| 26.5 | % |
| Adjusted EBITDA margin | |
| 10.9 | % | |
| 12.9 | % | |
| | |
| Rehabilitation Hospital | |
| | | |
| | | |
| | |
| Number of hospitals operated – end of period(a) | |
| 33 | | |
| 34 | | |
| | |
| Revenue (,000) | |
$ | 719,419 | | |
$ | 816,240 | | |
| 13.5 | % |
| Number of patient days(b)(c) | |
| 330,142 | | |
| 350,724 | | |
| 6.2 | % |
| Number of admissions(b)(d) | |
| 23,363 | | |
| 25,039 | | |
| 7.2 | % |
| Revenue per patient day(b)(e) | |
$ | 2,001 | | |
$ | 2,119 | | |
| 5.9 | % |
| Occupancy rate(b)(f) | |
| 84 | % | |
| 84 | % | |
| 0.0 | % |
| Adjusted EBITDA (,000) | |
$ | 155,531 | | |
$ | 183,471 | | |
| 18.0 | % |
| Adjusted EBITDA margin | |
| 21.6 | % | |
| 22.5 | % | |
| | |
| Outpatient Rehabilitation | |
| | | |
| | | |
| | |
| Number of clinics operated – end of period(a) | |
| 1,946 | | |
| 1,925 | | |
| | |
| Working days(g) | |
| 191 | | |
| 192 | | |
| | |
| Revenue (,000) | |
$ | 890,679 | | |
$ | 930,696 | | |
| 4.5 | % |
| Number of visits(b)(h) | |
| 7,984,622 | | |
| 8,336,216 | | |
| 4.4 | % |
| Revenue per visit(b)(i) | |
$ | 100 | | |
$ | 100 | | |
| 0.0 | % |
| Adjusted EBITDA (,000) | |
$ | 89,395 | | |
$ | 82,016 | | |
| (8.3 | )% |
| Adjusted EBITDA margin | |
| 10.0 | % | |
| 8.8 | % | |
| | |
| Concentra | |
| | | |
| | | |
| | |
| Number of centers operated – end of period(b) | |
| 539 | | |
| 549 | | |
| | |
| Working days(g) | |
| 191 | | |
| 192 | | |
| | |
| Revenue (,000) | |
$ | 1,397,341 | | |
$ | 1,435,151 | | |
| 2.7 | % |
| Number of visits(b)(h) | |
| 9,766,881 | | |
| 9,628,515 | | |
| (1.4 | )% |
| Revenue per visit(b)(i) | |
$ | 135 | | |
$ | 140 | | |
| 3.7 | % |
| Adjusted EBITDA (,000) | |
$ | 293,046 | | |
$ | 299,313 | | |
| 2.1 | % |
| Adjusted EBITDA margin | |
| 21.0 | % | |
| 20.9 | % | |
| | |
| (a) | Includes managed locations. |
| (b) | Excludes managed locations. For purposes of the Concentra segment, onsite clinics are excluded. |
| (c) | Each patient day represents one patient occupying one bed for one day during the periods presented. |
| (d) | Represents the number of patients admitted to Select Medical’s hospitals during the periods presented. |
| (e) | Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated
by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical’s
hospitals, by the total number of patient days. |
| (f) | Represents the portion of our hospitals being utilized for patient care during the periods presented.
Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during
the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented. |
| (g) | Represents the number of days in which normal business operations were conducted during the periods presented. |
| (h) | Represents the number of visits in which patients were treated at Select Medical’s outpatient rehabilitation
clinics and Concentra centers during the periods presented. |
| (i) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated
by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes
of this computation for the Concentra segment, patient service revenue does not include onsite clinics. |
IX. Net Income to Adjusted EBITDA Reconciliation
For the Three and Nine Months Ended September 30, 2023 and
2024
(In thousands, unaudited)
The presentation of Adjusted
EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within
the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for
each of Select Medical’s segments. Adjusted EBITDA is not a measure of financial performance under accounting principles generally
accepted in the United States of America (“GAAP”). Items excluded from Adjusted EBITDA are significant components in understanding
and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for,
net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement
data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is
not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may
not be comparable to other similarly titled measures of other companies.
The following table reconciles
net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted
EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt,
stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity
in earnings (losses) of unconsolidated subsidiaries.
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2023 | | |
2024 | | |
2023 | | |
2024 | |
| Net income | |
$ | 60,816 | | |
$ | 81,015 | | |
$ | 237,933 | | |
$ | 292,948 | |
| Income tax expense | |
| 15,742 | | |
| 26,809 | | |
| 70,775 | | |
| 95,509 | |
| Interest expense | |
| 50,271 | | |
| 55,439 | | |
| 147,839 | | |
| 143,309 | |
| Equity in earnings of unconsolidated subsidiaries | |
| (11,561 | ) | |
| (33,069 | ) | |
| (30,618 | ) | |
| (49,805 | ) |
| Loss on early retirement of debt | |
| 14,692 | | |
| 10,939 | | |
| 14,692 | | |
| 10,939 | |
| Income from operations | |
| 129,960 | | |
| 141,133 | | |
| 440,621 | | |
| 492,900 | |
| Stock compensation expense: | |
| | | |
| | | |
| | | |
| | |
| Included in general and administrative | |
| 9,425 | | |
| 10,961 | | |
| 26,383 | | |
| 32,517 | |
| Included in cost of services | |
| 2,058 | | |
| 2,415 | | |
| 5,607 | | |
| 6,882 | |
| Depreciation and amortization | |
| 52,394 | | |
| 50,143 | | |
| 154,758 | | |
| 158,151 | |
| Concentra separation transaction costs(b) | |
| — | | |
| 817 | | |
| — | | |
| 3,265 | |
| Adjusted EBITDA | |
$ | 193,837 | | |
$ | 205,469 | | |
$ | 627,369 | | |
$ | 693,715 | |
| | |
| | | |
| | | |
| | | |
| | |
| Critical illness recovery hospital | |
$ | 46,362 | | |
$ | 50,763 | | |
$ | 188,631 | | |
$ | 238,536 | |
| Rehabilitation hospital | |
| 53,626 | | |
| 60,117 | | |
| 155,531 | | |
| 183,471 | |
| Outpatient rehabilitation | |
| 26,346 | | |
| 28,319 | | |
| 89,395 | | |
| 82,016 | |
| Concentra | |
| 98,907 | | |
| 101,571 | | |
| 293,046 | | |
| 299,313 | |
| Other(a) | |
| (31,404 | ) | |
| (35,301 | ) | |
| (99,234 | ) | |
| (109,621 | ) |
| Adjusted EBITDA | |
$ | 193,837 | | |
$ | 205,469 | | |
$ | 627,369 | | |
$ | 693,715 | |
| (a) | Other primarily includes general and administrative costs. |
| (b) | Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees
incurred in connection with the Company’s planned separation of the Concentra segment into a new, publicly traded company and are
included within general and administrative expenses on the Condensed Consolidated Statements of Operations. |
X. Reconciliation of Earnings per Common Share to Adjusted Earnings
per Common Share
For the Three and Nine Months Ended September 30, 2023 and
2024
(In thousands, except per share amounts, unaudited)
Adjusted net income attributable
to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted
net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing
financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted
earnings per common share are important to investors because they are reflective of the financial performance of Select Medical’s
ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to
common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for,
net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the
consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common
shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying
calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable
to other similarly titled measures of other companies.
The following tables reconcile
net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to
common shares and adjusted earnings per common share on a fully diluted basis.
| | |
Three Months Ended September 30, | |
| | |
2023 | | |
Per Share(a) | | |
2024 | | |
Per Share(a) | |
| Net income attributable to common shares(a) | |
$ | 46,458 | | |
$ | 0.38 | | |
$ | 53,483 | | |
$ | 0.43 | |
| Adjustments:(b) | |
| | | |
| | | |
| | | |
| | |
| Loss on early retirement of debt, net of tax | |
| 10,022 | | |
| 0.08 | | |
| 7,697 | | |
| 0.06 | |
| Concentra separation transaction costs, net of tax | |
| — | | |
| — | | |
| 574 | | |
| 0.00 | |
| Adjusted net income attributable to common shares | |
$ | 56,480 | | |
$ | 0.46 | | |
$ | 61,755 | (c) | |
$ | 0.50 | (c) |
| | |
Nine Months Ended September 30, | |
| | |
2023 | | |
Per Share(a) | | |
2024 | | |
Per Share(a) | |
| Net income attributable to common shares(a) | |
$ | 190,067 | | |
$ | 1.55 | | |
$ | 221,153 | | |
$ | 1.78 | |
| Adjustments:(b) | |
| | | |
| | | |
| | | |
| | |
| Loss on early retirement of debt, net of tax | |
| 10,016 | | |
| 0.08 | | |
| 7,695 | | |
| 0.06 | |
| Concentra separation transaction costs, net of tax | |
| — | | |
| — | | |
| 2,325 | | |
| 0.02 | |
| Adjusted net income attributable to common shares | |
$ | 200,083 | | |
$ | 1.63 | | |
$ | 231,173 | | |
$ | 1.86 | |
| (a) | Net income attributable to common shares and earnings per common share are calculated based on the weighted
average common shares outstanding, as presented in table III. |
| (b) | Adjustments to net income attributable to common shares include estimated income tax and non-controlling
interest impacts and are calculated based on the diluted weighted average common shares outstanding. The estimated income tax impact,
which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes
both current and deferred income tax expense or benefit. |
| (c) | Does not total due to rounding. |
XI. Net Income to Adjusted EBITDA and Earnings per Common Share
to Adjusted Earnings per Common Share
Reconciliations
Business Outlook for the Year Ending December 31, 2024
(In millions, unaudited)
The following are reconciliations
of full year 2024 Adjusted EBITDA and adjusted earnings per common share expectations as computed at the low and high points of the range
to the closest comparable GAAP financial measure. Refer to table IX and X for discussion of Select Medical’s use of Adjusted EBITDA
and adjusted earnings per common share in evaluating financial performance. Refer to table IX for the definition of Adjusted EBITDA. Each
item presented in the below table is an estimation of full year 2024 expectations.
| | |
Range | |
| Non-GAAP Measure Reconciliation | |
Low | | |
High | |
| Net income attributable to Select Medical | |
$ | 260 | | |
$ | 274 | |
| Net income attributable to non-controlling interests | |
| 83 | | |
| 85 | |
| Net income | |
| 343 | | |
| 359 | |
| Income tax expense | |
| 110 | | |
| 115 | |
| Interest expense | |
| 199 | | |
| 199 | |
| Equity in earnings of unconsolidated subsidiaries | |
| (61 | ) | |
| (62 | ) |
| Loss on early retirement of debt | |
| 11 | | |
| 11 | |
| Income from operations | |
| 602 | | |
| 622 | |
| Stock compensation expense | |
| 51 | | |
| 51 | |
| Depreciation and amortization | |
| 209 | | |
| 209 | |
| Concentra separation transaction costs(a) | |
| 3 | | |
| 3 | |
| Adjusted EBITDA | |
$ | 865 | | |
$ | 885 | |
| | |
Range | |
| Non-GAAP Measure Reconciliation | |
Low | | |
High | |
| Basic and diluted earnings per common share | |
$ | 2.01 | | |
$ | 2.12 | |
| Adjustments: | |
| | | |
| | |
| Loss on early retirement of debt, net of tax | |
| 0.06 | | |
| 0.06 | |
| Concentra separation transaction costs, net of tax (a) | |
| 0.02 | | |
| 0.02 | |
| Adjusted earnings per common share | |
$ | 2.09 | | |
$ | 2.20 | |
| (a) | Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees
incurred in connection with the Company’s planned separation of the Concentra Segment into a new, publicly traded company and are
included within general and administrative expenses on the Condensed Consolidated Statements of Operations. The transaction costs reflect
the costs incurred by the Company during the nine months ended September 30, 2024, and they do not include an estimate of costs to
be incurred during the remainder of 2024. |
v3.24.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Select Medical (NYSE:SEM)
過去 株価チャート
から 10 2024 まで 11 2024
Select Medical (NYSE:SEM)
過去 株価チャート
から 11 2023 まで 11 2024
